Alzheimer’s Disease and the Brain’s N8 Immune System

Alzheimer’s Disease and the Brain’s N8 Immune System

Statistics show that every 65 seconds someone in America develops Alzheimer’s disease. Although Alzheimer’s typically affects the population over the age of 65, early onset Alzheimer’s is becoming more prevalent, with cases as early as 30 years of age. The disease manifests when abnormal plaques and tangles develop in the central nervous system and cause blockage of neurotransmission between nerve cells. Scientists have characterized many different types and severities of Alzheimer’s symptoms based on cell cycle re-entry causing tau protein formation, A-beta amyloid plaquing, and mitochondrial dysfunction.

Early signs and symptoms may include difficulty remembering new tasks and information and problems performing regular activities of daily living. Later symptoms of Alzheimer’s include memory failure, personality changes, disorientation, mood and behavior changes, deepening confusion about events, time and place, difficulty speaking, swallowing, and walking.

Currently, there is no drug or formal cure for Alzheimer’s disease, and most therapy centered around behavior and cognitive therapy.

NEW RESEARCH has stated that the human endocannabinoid system (ECS) maintains a key role in the pathophysiology of Alzheimer’s disease because of its influence on the IMMUNE SYSTEM in the BRAIN. Endogenous cannabinoids and cannabinoid-like molecules act on the CB1 receptors in modulating neurotransmission and are plentiful within the central nervous system. Also critical to the progression of Alzheimer’s disease is the role of CB2 receptors on the immune cells that are effectively cleaning up metabolic waste and any pathogenic material in the brain. Cannabidiol (CBD) and other non-psychoactive and psychoactive cannabinoids are able to penetrate the blood-brain barrier in order to act on these CB1 and CB2 receptors. Studies show CBD exerts a combination of effects on the brain in fighting against Alzheimer’s, including neuroprotection, anti-oxidation, and anti-apoptotic effects against beta-amyloid plaques and tau protein formation.The body is INNATELY able to maintain the proper inflammatory response in the central nervous system when there is adequate content of cannabinoid influence on the immune cells in the brain, especially the astrocytes.

In order to properly fuel the endocannabinoid system, the body requires proper NUTRIENTS. Plant-based hemp oil with high CBD content has been shown to improve motor activity, reduce the invasion of foreign material to the CNS and increased microglial activity. While there is not an established ideal serving size, researchers have confirmed that large servings up to 1,500mg per day have been well tolerated, without negative long-term side effects or adverse reactions.

To learn more about you can start to supplement your human endocannabinoid system to combat Alzheimer’s, visit our website at n8hemp.com

The article is not meant to diagnose, prescribe, treat, mitigate, or cure any disease or condition. Please consult with your physician if you have questions about CBD or Alzheimer’s.

 

Leave a Reply